Sandoz Group AG (FRA:D8Y0) Net Margin % : 0.77% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Sandoz Group AG's Net Income for the three months ended in Dec. 2023 was €71 Mil. Sandoz Group AG's Revenue for the three months ended in Dec. 2023 was €9,151 Mil. Therefore, Sandoz Group AG's net margin for the quarter that ended in Dec. 2023 was 0.77%.

The historical rank and industry rank for Sandoz Group AG's Net Margin % or its related term are showing as below:

FRA:D8Y0' s Net Margin % Range Over the Past 10 Years
Min: 0.77 Med: 4.94 Max: 9.11
Current: 0.77

FRA:D8Y0's Net Margin % is ranked worse than
58.04% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 3.27 vs FRA:D8Y0: 0.77

Sandoz Group AG Net Margin % Historical Data

The historical data trend for Sandoz Group AG's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Net Margin % Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Net Margin %

9.11

0.77

Sandoz Group AG Quarterly Data
	Dec22	Dec23
Net Margin %	9.11	0.77

Competitive Comparison of Sandoz Group AG's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Net Margin % distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's Net Margin % falls into.

Sandoz Group AG Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Sandoz Group AG's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	70.609	/	9150.743
	=	0.77 %

Sandoz Group AG's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	70.609	/	9150.743
	=	0.77 %

Sandoz Group AG (FRA:D8Y0) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Sandoz Group AG Net Margin % Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (FRA:D8Y0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (FRA:D8Y0) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZNY:USA SDZz:UK SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (FRA:D8Y0) Headlines

No Headlines